Management ChangeJul 15, 2026, 04:12 PM
Vaxcyte Appoints John Markels to Board; Heath Lukatch Retires
AI Summary
Vaxcyte, Inc. announced that Heath Lukatch notified the Board of Directors of his retirement, effective July 16, 2026. His departure was not due to any disagreement with the company. Concurrently, the Board appointed John Markels as a Class II director, effective the same date. Dr. Markels will also serve on the Audit Committee and Compensation Committee and qualifies as an independent director.
Key Highlights
- Heath Lukatch retired from Vaxcyte's Board of Directors, effective July 16, 2026.
- Dr. Lukatch's retirement was not due to any disagreement with the Company.
- John Markels was appointed to the Board as a Class II director, effective July 16, 2026.
- Dr. Markels' term will expire at the 2028 annual meeting of stockholders.
- Dr. Markels was appointed to the Audit Committee and Compensation Committee.
- Dr. Markels qualifies as an independent director under Nasdaq rules.
- Dr. Markels will receive compensation under the Company's non-employee director program, with an annual equity grant value of $430,000.
Price Impact
More from PCVX